Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaust Limited ( (AU:NUZ) ) has provided an update.
Neurizon Therapeutics Limited has announced the application for quotation of 42,249,999 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a transaction previously announced, and the securities are set to be issued on September 24, 2025. The announcement signifies a strategic step for Neurizon Therapeutics in enhancing its market presence and potentially increasing its capital base, which could have implications for its stakeholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Average Trading Volume: 316,811
Technical Sentiment Signal: Sell
Current Market Cap: A$73.85M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.